Listed

Corbus Pharmaceuticals Holdings, Inc.: Form 10-Q for the period ended Jun 30, 2026

Filed with the SEC on Aug 6, 2026 and accepted by EDGAR at Aug 6, 2026, 16:35 ET.

Share

Management's discussion and analysis

As filed, 36,449 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

The following discussion and analysis of our financial condition and results of operations should be read together with our financial statements and the related notes and the other financial information included elsewhere in this Quarterly Report. This discussion contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere in this Quarterly Report, particularly those under "Risk Factors."

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

This report on Form 10-Q contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify these forward-looking statements through our use of words such as "may," "can," "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential" and other similar words and expressions of the future.

There are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking statement made by us. These factors include, but are not limited to:

  • our history of operating losses;
  • our current and future capital requirements and our ability to satisfy our capital needs;
  • our ability to complete required clinical trials of our product and obtain approval from the U.S. Food and Drug Administration (the "FDA") or other regulatory agents in different jurisdictions;
  • our ability to internally develop new product candidates, intellectual property, and other product candidates we may acquire and/or license;
  • our ability to maintain or protect the validity of our patents and other intellectual property;
  • our ability to retain key executive members;
  • interpretations of current laws and the passages of future laws;
  • acceptance of our business model by investors;
  • the accuracy of our estimates regarding expenses and capital requirements; and
  • our ability to adequately support growth.

The foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein or risk factors that we are faced with that may cause our actual results to differ from those anticipated in our forward-looking statements. Please see "Risk Factors" for additional risks which could adversely impact our business and financial performance.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations, beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations, beliefs, or projections will result or be achieved or accomplished.

  • 19-

Overview

Corbus Pharmaceuticals Holdings, Inc. (the "Company," "Corbus," "we," "us," or "our") is a clinical-stage company focused on developing new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Our pipeline includes CRB-701, a next-generation antibody drug conjugate ("ADC") for the treatment of Nectin-4-expressing tumors and CRB-913, an orally delivered highly peripherally restricted cannabinoid type-1 ("CB1") inverse agonist for the treatment of obesity.

Our pipeline:

  • CRB-701 (SYS6002) is a next-generation clinical-stage ADC that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E ("MMAE"). In February 2023, we obtained a license from CSPC Megalith Biopharmaceutical Co. Ltd. (“CSPC”), a subsidiary of CSPC Pharmaceutical Group Limited, to develop and commercialize the drug in the United States (“U.S.”), Canada, the European Union (including the European Free Trade Area), the United Kingdom (“U.K.”) and Australia. We are conducting a Phase 1/2 study in the U.S. and Europe (the "Western study") enrolling patients with advanced solid tumors associated with Nectin-4 expression. In June 2025, we began dosing participants in the PD-1 combination arm with CRB-701 in combination with Keytruda® (pembrolizumab). We received fast track designation for CRB-701 from the FDA for the treatment of relapsed or refractory metastatic cervical cancer in December 2024 and in recurrent or metastatic head and neck squamous cell carcinoma (“HNSCC”) previously treated with platinum-based chemotherapy and an anti-PD(L)-1 therapy in September 2025. CRB-701 is currently being investigated by CSPC in a Phase 3 clinical trial in patients with cervical cancer in China (the "China study").

We presented updated clinical data at the 2026 American Society of Clinical Oncology ("ASCO") Annual Meeting held from May 29 – June 2 in Chicago, IL. The new data demonstrate robust activity in the second line ("2L") setting of two solid tumor types that express high levels of Nectin-4 and are primarily driven by human papilloma virus ("HPV"): oropharyngeal squamous cell carcinoma ("OPSCC"), a type of HNSCC, and cervical cancer. The data is derived from an April 1, 2026 data cut with a total safety population of 317 patients encompassing all tumor types and all doses. A total of 75 patients with HNSCC and 72 patients with cervical cancer were enrolled at the 2.7 mg/kg and 3.6 mg/kg doses. The CRB-701 dose expansion phase of the Phase 1/2 Western study is ongoing. The FDA has cleared the start of the Company's registrational study for CRB-701 in 2L OPSCC ("TEMPO-1") and enrollment is expected to begin in September 2026. In addition, we also anticipate reporting data with CRB-701 in combination with Keytruda® in first-line OPSCC patients in Q1 2027 to support potential further registration-enabling trials.

  • CRB-913 is an orally delivered highly peripherally restricted CB1 inverse agonist for the treatment of obesity. CB1 inverse agonism is a clinically validated mechanism to induce weight loss and is a distinct mechanism of action separate from GLP-1s and the incretin class. CRB-913 has been specifically formulated to shift the drug exposure from the brain to the periphery to improve safety and tolerability, including reducing gastrointestinal ("GI") adverse events observed in the incretin class. We completed a single ascending dose (“SAD”) and multiple ascending dose (“MAD”) Phase 1a study in December 2025. The SAD portion of the trial enrolled 64 participants across 8 cohorts. The MAD portion enrolled 48 participants across 4 cohorts, including a dedicated obese cohort. The highest SAD dose tested was 600 mg/day, and the highest MAD dose tested was 150 mg/day. In the dedicated obese MAD cohort (150 mg/day), all CRB-913-treated participants (n=9), and none in the placebo group (n=3), experienced weight loss. The CRB-treated participants achieved a mean 2.9% placebo-adjusted weight loss by Day 14. Weight loss started early and deepened with time. CRB-913 was safe and well-tolerated across all cohorts and all doses studied, including demonstrating a very favorable GI profile with no reports of vomiting, constipation or nausea. Daily neuropsychiatric assessments using CSSRS, PHQ-9, and GAD-7 were negative. We initiated a Phase 1b dose-range finding study (“CANYON-1”) in December 2025. The Phase 1b study plans to follow 240 U.S. patients randomized into 4 arms (placebo, 20 mg, 40 mg, and 60 mg) over a 12-week treatment period followed by a 4-week safety follow-up. The last patient completed their last clinical visit in August 2026. We remain on track to report data in September 2026.

Our pipeline formerly included CRB-601, a potent and selective anti-αvβ8 integrin monoclonal antibody for the treatment of solid tumors. CRB-601 is an anti-αvβ8 monoclonal antibody that blocks the activation of latent TGFβ present on cancer cells in the tumor microenvironment. CRB-601 was being evaluated as a potential treatment for patients with solid tumors in combination with existing therapies, including checkpoint inhibitors. We completed a Phase 1 dose escalation study. In November 2025, we presented a study-in-progress poster at the 2025 Society for Immunotherapy of Cancer conference. We have deprioritized the program and do not plan to enroll additional patients.

  • 20-

Recent Developments

Open Market Sale Agreement

On May 31, 2023, we entered into Amendment No. 1 to the Open Market Sale Agreement originally dated August 6, 2020 (as amended, the "Open Market Sale Agreement") with Jefferies LLC ("Jefferies"), as sales agent. Under the Open Market Sale Agreement, we may issue and sell, from time to time through Jefferies, shares of its common stock having an aggregate offering price of up to $150.0 million. During the three and six months ended June 30, 2026, we sold an aggregate of 894,044 shares of common stock, under the Open Market Sale Agreement, for net proceeds of approximately $9.1 million. As of June 30, 2026, approximately $59.7 million was available for issuance and sale under the Open Market Sale Agreement and we retain the ability to increase this amount at any time by filing a new or additional prospectus supplement, without any contractual or other limitation on our use of this facility. From July 1, 2026, through the date of filing, we sold 738,707 shares of its common stock pursuant to the Open Market Sale Agreement for which we received net proceeds of approximately $6.7 million.

April 2026 Lease Agreement

On April 1, 2026, we entered into the third amendment to our existing lease of office space in Norwood, Massachusetts (the "April 2026 Lease Agreement"). The April 2026 Lease Agreement extends the term of the lease to February 29, 2032, with an option to extend the lease term for an additional period of five years upon notice to the landlord. In addition, the April 2026 Lease Agreement reduces the leased space from 62,756 square feet to 36,471 square feet beginning on December 1, 2026, with new monthly base rent of approximately $65,000 per month beginning March 1, 2027, subject to annual base rent escalation clauses during the lease term.

CRB-701 License Agreement Milestone Payment

In April 2026, we paid CSPC Megalith Biopharmaceutical Co., Ltd. ("CSPC") $10.0 million pursuant to the achievement of a development milestone under our license agreement with CSPC (the "CSPC License Agreement") relating to CRB-701, our next-generation antibody drug conjugate targeting Nectin-4. We are obligated to pay remaining potential milestone payments to CSPC totaling up to $120.0 million based upon the achievement of specified development and regulatory milestones and up to $555.0 million in potential commercial milestone payments. In addition, we are obligated to pay CSPC royalties in the low double digits based on net sales of any Licensed Products, as defined in the CSPC License Agreement.

Amendment to 2024 Equity Compensation Plan

On May 13, 2026, we held our annual meeting of stockholders (the “Annual Meeting”). At the Annual Meeting, our stockholders approved the amendment (the “2024 Plan Amendment”) to our 2024 Equity Compensation Plan (the “2024 Equity Compensation Plan”) to increase the number of shares of common stock authorized for issuance thereunder by 3,000,000 shares to 5,000,000. Our board of directors (the “Board”) had previously approved the 2024 Plan Amendment on March 20, 2026, subject to stockholder approval, and the 2024 Plan Amendment became effective upon such stockholder approval.

Director Appointment

On May 13, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed Brent Pfeiffenberger to serve as a member of the Board. Subsequently, on May 19, 2026, we granted Brent Pfeiffenberger the following initial equity awards under the 2024 Equity Compensation Plan in connection with his appointment to the Board: (i) a nonqualified stock option to purchase 24,700 shares of our common stock at an exercise price equal to the closing price of a share of common stock on the Nasdaq Capital Market on May 19, 2026, which option vests in three equal annual installments on each of the first three anniversaries of the grant date, subject to Dr. Pfeiffenberger’s continued service to the Company through each applicable vesting date, and expires on May 19, 2036; and (ii) a restricted stock unit award covering 7,500 shares of our common stock, which vests in three equal annual installments on each of the first three anniversaries of the grant date, subject to Dr. Pfeiffenberger’s continued service to the Company through each applicable vesting date.

  • 21-

Appointment of Chief Business Officer

Effective May 21, 2026, we entered into an employment agreement with Nishant Saxena, which is effective for a period of two (2) years from the date thereof. Mr. Saxena’s employment agreement provides for him to serve as Chief Business Officer. Pursuant to the terms of his employment agreement, Mr. Saxena was granted 192,300 stock options to acquire shares of our common stock at an exercise price equal to the closing price of a share of common stock on the Nasdaq Capital Market on May 21, 2026, which will vest 25% after one year of employment and thereafter monthly over the following 36 months, subject to continuous employment with the Company, and 58,300 restricted stock units, which will vest 25% on each of the first, second, third and fourth annual anniversary of the award date, subject to continuous employment with the Company.

2026 Inducement Award Plan

On June 17, 2026, the Board adopted the 2026 Inducement Award Plan (the “Inducement Plan”), which will be administered by the Board and/or the Compensation Committee of the Board. The Inducement Plan was adopted without stockholder approval pursuant to Nasdaq Listing Rule 5635(c)(4). Any awards issued pursuant to the Inducement Plan will be issued pursuant to the “inducement” grant exception under 5635(c)(4) of the Marketplace Rules of the Nasdaq Stock Market LLC, as inducements that are material to employees entering into employment with the Company.

Appointment of Chief Medical Officer

On July 2, 2026, we entered into an employment agreement with Leonardo Viana Nicacio, MD, effective August 3, 2026, which is effective for a period of two (2) years. Dr. Nicacio’s employment agreement provides for him to serve as Chief Medical Officer. As an inducement to Dr. Nicacio accepting this position, he will be granted an employment inducement award of an aggregate grant date fair value of $2.1 million, consisting of approximately 75% stock options and approximately 25% restricted stock units, pursuant to the Inducement Plan, in accordance with Rule 5635(c)(4) of the Nasdaq Stock Market LLC.

Financial Operations Overview

We are a clinical-stage company focused on developing new therapies in oncology and obesity and have not generated any revenues from the sale of products. We do not expect to generate revenue from product sales unless and until we successfully complete development and obtain regulatory approval for the marketing of one of our product candidates, which we expect will take a number of years and is subject to significant uncertainty. We have never been profitable and at June 30, 2026, we had an accumulated deficit of approximately $613.4 million. Our net losses for the three months ended June 30, 2026 and 2025, were approximately $35.0 million and $17.7 million, respectively. Our net losses for the six months ended June 30, 2026 and 2025 were approximately $58.0 million and $34.6 million, respectively.

We expect to continue to incur significant expenses for the foreseeable future. We expect our expenses to increase in connection with our ongoing activities, particularly as we continue the research and development of our product candidates. We will continue to incur significant operating losses as we move into the clinical phase and, accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations through public or private equity, debt financings or other sources, which may include government grants and collaborations with third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We will need to generate significant revenues to achieve profitability, and we may never do so.

We expect to continue to incur operating losses for at least the next several years in connection with our ongoing activities, as we:

  • conduct pre-clinical and clinical trials for our product candidates;
  • continue our research and development efforts; and
  • manufacture and purchase drugs for clinical studies.
  • 22-

Critical Accounting Policies and Estimates

Our condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. The preparation of these financial statements requires management to make estimates, assumptions, and judgments that affect the reported amounts of assets, liabilities, revenue, costs of expenses and related disclosures in the condensed consolidated financial statements. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates and judgments on historical experience, current economic and industry conditions and on various other factors that are believed to be reasonable under the circumstances. This forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions.

There have been no changes to the critical accounting estimates we identified in Item 7. Management's Discussion and Analysis of Financial Condition and Results of Operations in our Annual Report on Form 10-K for the year ended December 31, 2025, filed on March 9, 2026 (the “2025 Annual Report”).

Results of Operations

Comparison of Three Months Ended June 30, 2026 and 2025

Operating Expenses. The following table summarizes our operating expenses for the three months ended June 30, 2026 and 2025 (in thousands):

Three Months Ended June 30, 2026 2025 $ Change % Change
Research and development expense $31,175 $15,187 $15,988 105%
General and administrative expense 5,015 3,965 1,050 26%
Total operating expenses $36,190 $19,152 $17,038 89%

Research and Development. The following table summarizes our research and development expenses for the three months ended June 30, 2026 and 2025 (in thousands):

Program specific costs: Three Months Ended June 30, 2026 2025 $ Change % Change
CRB-701 $19,735 $5,173 $14,562 282%
CRB-913 7,870 3,788 4,082 108%
CRB-601 439 3,389 (2,950) -87%
Other drug development 107 126 (19) -15%
Total program specific costs 28,151 12,476 15,675 126%
Unallocated internal costs:
Personnel related 2,472 2,276 196 9%
Other unallocated 552 435 117 27%
Total research and development expenses $31,175 $15,187 $15,988 105%

Research and development expenses for the three months ended June 30, 2026 totaled $31.2 million, an increase of $16.0 million from $15.2 million recorded for the three months ended June 30, 2025.

Total program-specific costs increased by $15.7 million for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025. Costs related to CRB-701 increased by $14.6 million primarily as a result of the $10.0 million development milestone payment made to CSPC in Q2 2026, as well as higher clinical costs as additional participants are enrolled in the ongoing Phase 1/2 clinical trial and we begin preparing for the start of TEMPO-1. CRB-913 costs increased by $4.1 million primarily due to higher clinical costs as the Phase 1b portion of the clinical study has completed enrollment and treatment progresses. Costs related to CRB-601 decreased by $3.0 million as the Phase 1 dose escalation study was completed and no additional patients were enrolled in fiscal year 2026.

  • 23-

Personnel-related costs increased by $0.2 million for the three months ended June 30, 2026 as compared to the three months ended June 30, 2025. The increase is primarily due to an increase in headcount.

We have a subsidiary in each of the U.K. and Australia. During the three months ended June 30, 2026 and 2025, approximately 20% and 31% of research and development expenses, respectively, were recorded in these entities.

General and Administrative. General and administrative expenses for the three months ended June 30, 2026 totaled $5.0 million, an increase of $1.0 million from $4.0 million recorded for the three months ended June 30, 2025. The increase in fiscal quarter 2026 as compared to fiscal quarter 2025 was attributable to an increase in compensation costs of $0.4 million primarily due to an increase in headcount, an increase of $0.3 million in legal costs and a $0.2 million increase in recruiting expense primarily due to search costs for open positions in the current year.

Other Income, Net. The following table summarizes our total other income, net for the three months ended June 30, 2026 and 2025 (in thousands):

Three Months Ended June 30, 2026 2025 $ Change % Change
Interest and investment income, net $1,164 $1,314 $(150) -11%
Other (expense) income, net (11) 176 (187) -106%
Total other income, net $1,153 $1,490 $(337) -23%

Total other income, net for the three months ended June 30, 2026 totaled $1.2 million, a decrease of $0.3 million from $1.5 million recorded for the three months ended June 30, 2025. The decrease in 2026 as compared to 2025 was primarily attributable to foreign exchange and a decrease in interest and investment income.

Comparison of Six Months Ended June 30, 2026 and 2025

Operating Expenses. The following table summarizes our operating expenses for the six months ended June 30, 2026 and 2025 (in thousands):

Six Months Ended June 30, 2026 2025 $ Change % Change
Research and development expense $50,994 $30,829 $20,165 65%
General and administrative expense 9,500 8,098 1,402 17%
Total operating expenses $60,494 $38,927 $21,567 55%

Research and Development. The following table summarizes our research and development expenses for the six months ended June 30, 2026 and 2025 (in thousands):

Program specific costs: For the Six Months Ended June 30, 2026 2025 $ Change % Change
CRB-701 $28,171 $12,306 $15,865 129%
CRB-913 14,231 6,541 7,690 118%
CRB-601 2,187 6,626 (4,439) -67%
Other drug development 221 246 (25) -10%
Total program specific costs 44,810 25,719 19,091 74%
Unallocated internal costs:
Personnel related 5,160 4,258 902 21%
Other unallocated 1,024 852 172 20%
Total research and development expenses $50,994 $30,829 $20,165 65%
  • 24-

Research and development expenses for the six months ended June 30, 2026 totaled $51.0 million, an increase of $20.2 million from $30.8 million recorded for the six months ended June 30, 2025.

Total program-specific costs increased by $19.1 million for the six months ended June 30, 2026 as compared to the six months ended June 30, 2025. Costs related to CRB-701 increased by $15.9 million primarily as a result of the $10.0 million development milestone paid to CSPC in Q2 2026, as well as higher clinical costs as additional participants are enrolled in the ongoing Phase 1/2 clinical trial and we begin preparing for the start of TEMPO-1. CRB-913 costs increased by $7.7 million primarily due to ongoing treatment in the Phase 1b portion of the clinical study, which began enrollment in December 2025 and ended in April 2026. Costs related to CRB-601 decreased by $4.4 million as the Phase 1 dose escalation study was completed and no additional patients were enrolled in fiscal year 2026.

Personnel-related costs increased by $0.9 million for the six months ended June 30, 2026 as compared to the six months ended June 30, 2025. The increase is primarily due to an increase in headcount.

We have a subsidiary in each of the U.K. and Australia. During the six months ended June 30, 2026 and 2025, approximately 23% and 35% of research and development expenses, respectively, were recorded in these entities.

General and Administrative. General and administrative expenses for the six months ended June 30, 2026 totaled $9.5 million, an increase of $1.4 million from $8.1 million recorded for the six months ended June 30, 2025. The increase in 2026 as compared to 2025 was attributable to an increase in compensation costs of $0.6 million primarily due to an increase in headcount, an increase of $0.4 million in legal costs and a $0.3 million increase in recruiting expense primarily due to search costs for open positions in the current year.

Other Income, Net. The following table summarizes our total other income, net for the six months ended June 30, 2026 and 2025 (in thousands):

Six Months Ended June 30, 2026 2025 $ Change % Change
Interest and investment income, net $2,566 $2,995 $(429) -14%
Other income, net (78) 1,292 (1,370) -106%
Total other income, net $2,488 $4,287 $(1,799) -42%

Total other income, net for the six months ended June 30, 2026 totaled $2.5 million, a decrease of $1.8 million from $4.3 million recorded for the six months ended June 30, 2025. The decrease in 2026 as compared to 2025 was primarily attributable to a $1.1 million employee retention credit recorded during 2025. No employee retention credit was recorded during 2026. The remaining decrease in 2026 as compared to 2025 was primarily attributable to foreign exchange and a decrease in interest and investment income.

Liquidity and Capital Resources

Since inception, we have experienced negative cash flows from operations. We have financed our operations primarily through sales of equity-related securities. At June 30, 2026, our accumulated deficit since inception was approximately $613.4 million.

At June 30, 2026, we had total current assets of approximately $122.8 million and current liabilities of approximately $21.5 million, resulting in working capital of approximately $101.3 million. Of our total cash, cash equivalents, investments, and restricted cash of $118.3 million at June 30, 2026, approximately $115.7 million was held within the U.S.

Cash Flows

The following table summarizes our cash flows for the six months ended June 30, 2026 and 2025 (in thousands):

  • 25-
Six Months Ended June 30, 2026 2025
Net cash used in operating activities $(55,197) $(33,020)
Net cash provided by investing activities 40,715 35,866
Net cash provided by financing activities 9,075 —
Net (decrease) increase in cash, cash equivalents, and restricted cash $(5,407) $2,846

Net cash used in operating activities for the six months ended June 30, 2026 was $55.2 million, which includes a net loss of $58.0 million, adjusted for non-cash expenses of $3.3 million primarily related to stock-based compensation expense, and $0.5 million of cash used in net working capital items principally due to an increase in accounts payable and prepaid expenses and a decrease in accrued expenses.

Cash provided by investing activities for the six months ended June 30, 2026 totaled $40.7 million, which was principally related to proceeds from sales and maturities of marketable securities.

Cash provided by financing activities for the six months ended June 30, 2026 totaled $9.1 million, which was related to the issuance of common stock. During the six months ended June 30, 2026, we sold 894,044 shares of our common stock pursuant to the Open Market Sale Agreement for which we received net proceeds of approximately $9.1 million. No cash was provided by financing activities for the six months ended June 30, 2025.

Future Funding Requirements

Based on current operating plans and assumptions regarding clinical timelines and other planned expenditures, we expect our cash, cash equivalents, and investments of approximately $117.9 million at June 30, 2026 will be sufficient to meet our operating and capital requirements through at least twelve months from the issuance of this Quarterly Report on Form 10-Q.

We will need to raise significant additional capital to continue to fund operations, including pre-clinical and clinical costs for our product candidates. We may seek to sell common or preferred equity or convertible debt securities, enter into a credit facility or another form of third-party funding or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government grants. The sale of equity and convertible debt securities may result in dilution to our stockholders and certain of those securities may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations. Any other third-party funding arrangement could require us to relinquish valuable rights.

The source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically, on the progress of our clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate expenses including some or all of our planned clinical trials.

Off-Balance Sheet Arrangements

We do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that is material to investors, other than future royalty payments under license agreements discussed as follows:

License Agreement with Jenrin

Pursuant to the terms of the license agreement (the "Jenrin License Agreement") with Jenrin Discovery, LLC ("Jenrin"), we are obligated to pay potential milestone payments to Jenrin totaling up to $18.4 million for each compound we elect to develop based upon the achievement of specified development and regulatory milestones. In addition, we are obligated to pay Jenrin royalties in the mid, single digits based on net sales of any Licensed Products, as defined in the Jenrin License Agreement, subject to specified reductions. A $0.4 million milestone payment was achieved in the first quarter of 2025 associated with the progression into a clinical trial for CRB-913 and paid during the second quarter of 2025. The Company is obligated to pay Jenrin up to $18.0 million in additional potential milestone payments for further development of CRB-913.

  • 26-

The Jenrin License Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term for such product in such country. Each royalty term begins on the date of the first commercial sale of the licensed product in the applicable country and ends on the later of seven years from such first commercial sale or the expiration of the last to expire of the applicable patents in that country. The Jenrin License Agreement may be terminated earlier in specified situations, including termination for uncured material breach of the Jenrin License Agreement by either party, termination by Jenrin in specified circumstances, termination by Corbus with advance notice, and termination upon a party’s insolvency or bankruptcy.

License Agreement with UCSF

Pursuant to the terms of the license agreement (the "UCSF License Agreement") with the Regents of the University of California, we are obligated to pay up to $150.8 million in remaining potential milestone payments based upon the achievement of specified development and regulatory milestones, excluding indication milestones for antibodies used for diagnostic products and services that will be an additional $50.0 thousand for each new indication. In addition, we are obligated to pay royalties in the lower, single digits based on net sales of any Licensed Products, as defined in the UCSF License Agreement, and any diagnostic products and services. During the first quarter of 2025, we paid $1.6 million under the UCSF License Agreement for previously achieved milestone payments.

The UCSF License Agreement will remain in effect until the expiration or abandonment of the last of the Patent Rights licensed. The Royalty Term is the duration of Patent Rights in that country covering the applicable Licensed Product or Licensed Services Sold in the country. The UCSF License Agreement may be terminated earlier in specified situations, including termination for material breach, termination by us with advance notice, and termination upon a party's bankruptcy.

License Agreement with CSPC

In April 2026, we paid CSPC $10.0 million pursuant to the achievement of a development milestone. Pursuant to the terms of the CSPC License Agreement, we are obligated to pay remaining potential milestone payments to CSPC totaling up to $120.0 million based upon the achievement of specified development and regulatory milestones and $555.0 million in potential commercial milestone payments. In addition, we are obligated to pay CSPC royalties in the low, double digits based on net sales of any Licensed Products, as defined in the CSPC License Agreement.

The CSPC License Agreement will remain in effect on a Licensed Product and on a country-by-country basis, until the expiration of the Royalty Term of the Licensed Product in the country. The Royalty Term is the period beginning from the First Commercial Sale of the Licensed Product in the country until the later of the expiration of the last-to-expire Valid Claim in any Licensor Patent in the country that Covers the Licensed product, 10 years after the date of the First Commercial Sale in the country, or expiration of the Regulatory Exclusivity for the Licensed Product in the country. The CSPC License Agreement may be terminated earlier in specified situations, including termination for material breach, termination by us with advance notice, and termination upon a party's bankruptcy.

Controls and procedures

As filed, 1,975 characters, with its headings, lists and tables. Extracted from the main document; charts and exhibits are in the original on sec.gov.

Evaluation of Our Disclosure Controls and Procedures

We maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms and to provide reasonable assurance that such information is accumulated and communicated to our management, our principal executive officer and our principal financial officer, to allow timely decisions regarding required disclosure. Our management, with the participation of our Chief Executive Officer and our Chief Financial Officer, has evaluated the effectiveness of our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act, as amended) as of the end of the period covered by this report.

  • 27-

Based on that evaluation, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures as of the end of the period covered by this report were effective in ensuring that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that the information required to be disclosed by us in such reports is accumulated and communicated to our management, including our Chief Executive Officer and our Chief Financial Officer, as appropriate to allow timely decisions regarding required disclosure.

Changes in Internal Control over Financial Reporting

There were no changes in our internal control over financial reporting (as defined in Rule 13a-15(f) of the Exchange Act) that occurred during the period to which this report relates that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

  • 28-

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2026-06-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2026-04-01 to 2026-06-30$31.2mus-gaap:ResearchAndDevelopmentExpense
Research and development6 months2026-01-01 to 2026-06-30$51.0mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2026-04-01 to 2026-06-30−$36.2mus-gaap:OperatingIncomeLoss
Operating income6 months2026-01-01 to 2026-06-30−$60.5mus-gaap:OperatingIncomeLoss
Net income3 months2026-04-01 to 2026-06-30−$35.0mus-gaap:NetIncomeLoss
Net income6 months2026-01-01 to 2026-06-30−$58.0mus-gaap:NetIncomeLoss
Diluted EPS3 months2026-04-01 to 2026-06-30−$1.81us-gaap:EarningsPerShareDiluted
Diluted EPS6 months2026-01-01 to 2026-06-30−$3.04us-gaap:EarningsPerShareDiluted
Basic EPS3 months2026-04-01 to 2026-06-30−$1.81us-gaap:EarningsPerShareBasic
Basic EPS6 months2026-01-01 to 2026-06-30−$3.04us-gaap:EarningsPerShareBasic
Diluted shares (weighted)3 months2026-04-01 to 2026-06-3019,407,688 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Diluted shares (weighted)6 months2026-01-01 to 2026-06-3019,059,092 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow6 months2026-01-01 to 2026-06-30−$55.2mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure6 months2026-01-01 to 2026-06-30$12.0kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2026-06-30$23.4mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2026-06-30$122.8mus-gaap:AssetsCurrent
Total assetsAt period end2026-06-30$127.0mus-gaap:Assets
Current liabilitiesAt period end2026-06-30$21.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2026-06-30$24.7mus-gaap:Liabilities
Shareholders' equityAt period end2026-06-30$102.2mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001193125-26-338274. Last ingested by Listed: Nov 14, 2026, 12:52 ET. Listed shows no prices and gives no investment advice.